BILBOMÁTICA, an ALTIA Company, is one of the companies participating in the European project LUCIA (Understanding Lung Cancer-Related Risk Factors and their Impact), which aims to understand the risk factors related to lung cancer and their impact. Specifically, the Spanish group is part of the consortium of companies formed by Technion – Israel Institute of Technology, Vicomtech, and Bilbomática, which is working to map the risk factors associated with the disease.
The project involves nine European countries and aims to manage lung cancer from the perspective of early diagnosis, prevention, and treatment, especially for relatively rare cancers. The consortium's work will result in recommendations to be integrated into the early diagnosis program and in methods for effectively addressing the disease.
The consortium, in which Bilbomática participates and which is led by Technion, will consider three main aspects in developing the risk factor map: individual factors, including lifestyle and exposure to pollutants; external factors, such as urban or urbanized areas, traffic, climate, and socioeconomic factors; and biological responses, such as aging and genetic, epigenetic, and metabolic changes. To achieve this, it has the participation of various healthcare organizations, including the Basque Health Service Osakidetza (BioCruces), the European Federation of Hospitals and Healthcare Services, the University Hospital of Liège, and the Andalusian Health Service (SAS).
BILBOMÁTICA, an ALTIA Company, as an expert in software development in the fields of cancer, interoperability of hospital information systems, processing of large volumes of clinical information and in developments oriented towards the experience of the medical professional user, will contribute to the project some of the software tools that are necessary after the analysis phases for the processing of prospective and retrospective patient data.
Specifically, BILBOMÁTICA is involved in the co-creation of the digital Biobank and in the integration of the software ecosystem tools, generating the health data platform that will support the collection of retrospective and prospective data from different health and social registries, as well as exposure data.
“In the LUCIA project, technology will be a key element in improving the early detection and management of lung cancer through the in-depth study of risk factors related to individual biological exposure. We at BILBOMÁTICA are very pleased to contribute the technological expertise and software necessary to improve prevention strategies, help implement screening programs, enhance diagnosis, and enable more precise medical approaches,” said Frank Guijarro, Head of R&D&I Projects at BILBOMÁTICA, an ALTIA Company.
More information about the LUCIA project can be found at this link .
The LUCIA project receives funding from the European Union's Horizon Europe research and innovation programme under grant agreement 101096473 .